PharmaResearch (CEO Kim Thinkyou, Kang Ki-seok) announced that “CONJURAN,” a polynucleotide (PN) based intra-articular injection, has received the medical device product approval from the Malaysian Medical Device Authority (MDA).
CONJURAN is a medical device that
uses DNA Optimizing Technology (DOT™) PN, a patented technology from PharmaResearch, that can help improve degenerative osteoarthritis by relieving pain and reducing
mechanical joint friction.
A related official from PharmaResearch stated that “we expect a high demand since Malaysia represents the
second largest market for medical devices in Southeast Asia after Thailand” and
“CONJURAN will establish itself as a new solution for knee pain in the
Southeast Asian market owing to its excellent technology and product
capabilities based on DOT™ PN.”
PharmaResearch is a regenerative medicine-based pharmaceutical biotechnology company that manufactures and sells pharmaceuticals, medical devices, cosmeceuticals, and dietary supplements based on DOT™ PDRN/PN, which are tissue-regenerating substances, such as REJURAN®, CLEVIEL®, CONJURAN®, REJURAN® cosmetic, Re-An® eye drops, and REJUDERMA®.